🚨 EXCLUSIVE: Hims board member David Wells on why he bought $1.2M of Hims

<p>Thanks to our partner:Superpower - https://superpower.com</p><p><br></p><p>In episode 72 of Hims House, Jonathan Stern interviews David Wells, Hims board member and former Netflix CFO, about his recent $1.2 million open-market purchase of Hims shares. Wells explains why he believes the company is at an inflection point after the Novo dispute and why the market may be missing the larger healthcare platform story. He discusses Hims’ mission, the broken cost and access structure of U.S. healthcare, and why he focuses more on longer-term cohorts and customer value than quarter-to-quarter CAC. The conversation covers the GLP-1 transition, peptides, acquisition pace, Andrew Dudum’s leadership, remote culture, AI, wearables, and what Hims can learn from Netflix’s disruption playbook. Wells also breaks down 10b5-1 insider selling plans, the promise of preventative scans, and why poor execution is the bear case that matters most.</p><p><br></p><p>00:00 - Sponsor: Superpower</p><p>01:07 - Meet David Wells</p><p>02:30 - Why he bought $1.2M in shares</p><p>05:58 - Building a mission-driven company</p><p>09:03 - Why he accepted the offer to join the board</p><p>10:45 - Financial metrics David is tracking</p><p>12:53 - Novo deal + GLP-1s</p><p>15:13 - Peptides: best, not first</p><p>19:45 - M&amp;A and execution risk</p><p>20:40 - What CEO Andrew Dudum does well</p><p>22:30 - Remote impact on company culture</p><p>24:22 - AI, tech, and wearables</p><p>29:55 - Lessons from Netflix</p><p>36:17 - Insider sales 10b5-1 explained</p><p>45:37 - Short interest and the bear case</p><p>48:23 - Hims in 2030</p><p><br></p><p>Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.</p>